Semaglutide (often misspelled as “semi-glutide”) is a prescription medication that mimics a natural gut hormone called GLP-1, which regulates appetite and blood sugar. Originally developed for type 2 diabetes, it became one of the most talked-about drugs in the world after clinical trials showed it could help people lose an average of 16% of their body weight. It’s sold under several brand names, including Ozempic, Wegovy, and Rybelsus.
How Semaglutide Works
After you eat, your gut releases a hormone called GLP-1 that tells your pancreas to produce insulin and signals your brain that you’re full. The problem is that natural GLP-1 breaks down in minutes. Semaglutide is an engineered version of this hormone designed to last much longer in your body, which is why the injectable form only needs to be taken once a week.
The drug works on two fronts. It lowers blood sugar by boosting insulin production when glucose levels are high, and it reduces appetite by acting on hunger-signaling pathways in the brain. This dual action is why it’s approved for both diabetes management and weight loss, depending on the brand and dose.
Brand Names and What They Treat
Semaglutide is sold under different names for different purposes:
- Ozempic is a once-weekly injection approved for adults with type 2 diabetes. It improves blood sugar control and reduces the risk of major cardiovascular events like heart attack and stroke in high-risk patients. It’s also approved to slow kidney disease progression in people with type 2 diabetes.
- Wegovy is a once-weekly injection approved for weight management in adults and children 12 and older. It’s also approved to lower the risk of heart attack and stroke, and for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH).
- Rybelsus is a daily oral tablet approved for type 2 diabetes. It carries the same diabetes and cardiovascular indications as Ozempic but comes in pill form.
The active ingredient is identical across all three brands. The differences come down to the dose, how it’s delivered, and which condition it’s prescribed for.
Injectable vs. Oral Formulations
Most people using semaglutide take the injectable version, a small once-weekly shot under the skin of the abdomen, thigh, or upper arm. It doesn’t matter whether you’ve eaten before or after the injection, and you can take it at any time of day.
The oral tablet works differently. Peptide drugs like semaglutide are normally destroyed by stomach acid, so the pill is co-formulated with a special absorption enhancer that protects the drug and helps it pass through the stomach lining. This comes with a trade-off: the pill has much lower bioavailability than the injection. To compensate, daily oral doses range from 7 to 14 mg, while injectable doses are only 1 to 2 mg per week.
Because absorption is fragile, the oral tablet must be taken on an empty stomach at least 30 minutes before any food, drink (other than a small sip of water), or other medications. For people who dislike needles this is a worthwhile trade-off, but the stricter routine is something to consider.
Weight Loss Results
Semaglutide’s weight loss effects were studied in a series of large clinical trials called the STEP program. In the STEP 3 trial, participants taking semaglutide alongside behavioral counseling lost an estimated 16% of their body weight over 68 weeks, compared to 5.7% in the placebo group. For someone weighing 250 pounds, that translates to roughly 40 pounds lost over about 16 months.
These results represent averages. Some people lose significantly more, others less. Weight tends to come off gradually over the first year and then plateaus. One important caveat: studies consistently show that weight tends to return after stopping the medication, which is why many prescribers treat it as a long-term therapy rather than a short course.
Blood Sugar Improvements
For people with type 2 diabetes, semaglutide lowers HbA1c (a measure of average blood sugar over three months) by 0.6 to 1.6 percentage points compared to other treatments, based on a pooled analysis of over 8,800 participants across multiple trials. That’s a clinically meaningful drop. An HbA1c reduction of 1 percentage point, for example, can significantly lower the risk of diabetes-related complications affecting the eyes, kidneys, and nerves.
Notably, this blood sugar benefit holds regardless of how well the kidneys are functioning, which matters because many people with long-standing diabetes also have some degree of kidney disease.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during the first few weeks and when the dose increases, then gradually improve as the body adjusts. This is one reason prescribers start at a low dose (typically 0.25 mg per week for the injectable) and increase it every four weeks rather than jumping straight to the full dose.
Less common but more serious concerns include inflammation of the pancreas (pancreatitis), gallbladder problems, and in rare cases, changes in vision for people with diabetic eye disease. Semaglutide also carries an FDA boxed warning based on animal studies showing an increased risk of thyroid tumors. It’s contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called Multiple Endocrine Neoplasia syndrome type 2.
Starting and Adjusting the Dose
Both Ozempic and Wegovy follow a gradual dose-escalation schedule. You start at 0.25 mg once weekly for four weeks, then the dose increases in steps every four weeks. This slow ramp-up is designed to minimize nausea and give your digestive system time to adapt. Most people reach their maintenance dose within four to five months.
If side effects are difficult to tolerate at a higher dose, prescribers will sometimes hold at the current level for an extra month before attempting another increase. Skipping the titration and jumping to a full dose is a common reason people have a rough experience with the medication.
Who Should Not Take It
Beyond the thyroid cancer contraindication, semaglutide is not recommended during pregnancy or while planning to become pregnant. Because it slows stomach emptying, it can interact with other oral medications by changing how quickly they’re absorbed. People with a history of pancreatitis should discuss their risk carefully before starting. And because semaglutide stimulates insulin release, combining it with other insulin-boosting diabetes medications can increase the risk of low blood sugar.